Baird reiterates Immunocore stock rating on combination therapy data
Baird maintained an Outperform rating and $84.00 price target for Immunocore (IMCR), citing positive Phase 1/2 data for a combination therapy in uveal melanoma. The stock trades at $29.13, with analysts noting potential undervaluation. IMCR reported $429M revenue over the last year, with 13% growth but no profitability. Five analysts revised earnings upwards.
